A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis

British Journal of Dermatology

Volumn 135, Issue 1, 1996, Pages 86-88

  Haroon, T S ^a,f   Hussain, I ^a   Aman, S ^a   Jahangir, M ^a   Kazmi, A H ^b   Sami, A R ^b   Nagi, A H ^c   Alvi, K H ^d   Iqbal, N ^d   Khan, K A ^e   Aziz, R ^e  

^a MAYO HOSPITAL   (Pakistan)

^b SERVICES HOSPITAL   (Pakistan)

^c KING EDWARD MEDICAL UNIVERSITY   (Pakistan)

^d Sind Social Security Institution   (Pakistan)

^e UNIVERSITY OF KARACHI   (Pakistan)

^f NONE   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

TERBINAFINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TINEA CAPITIS; TRICHOPHYTON;

EID: 8944237977     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb03613.x     Document Type: Article

References (13)

1. Meith H. The early development of allylamine antimycotics. J Dermatol Treat 1990; 1 (Suppl. 2): 5-6.
2. Clayton YM. The in vitro activity of terbinafine. Clin Exp Dermatol 1989; 14: 101-3.
3. Haroon TS, Hussain I, Mahmood A et al. An open clinical pilot study of the efficacy and safety of oral terbinafine in dry, noninflammatory tinea capitis. Br J Dermatol 1992; 126 (Suppl. 39): 47-50.
4. Haroon TS, Hussain I, Aman S et al. A randomized, double-bind comparative study of terbinafine vs. griseofulvin in tinea capitis. J Dermatol Treat 1995; 6: 167-9.
5. Nejjam F, Zagula M, Cabiac MD et al. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br J Dermatol 1995; 132: 98-105.
6. Faergemann J, Zehender H, Jones T et al. Terbinafine levels in serum, stratum corneum. dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat, Acta Derm Venereol (Stockh) 1990; 71: 322-6.
7. Ryder NS. The mechanism of action of terbinafine. Clin Exp Dermatol 1989; 14: 98-100.
8. Ryder NS. Terbinafine: Mode of action and properties of squalene epoxidase inhibitor. Br J Dermatol 1992; 126 (Suppl. 39): 2-7.
9. Villars V, Jones TC. Present status of the efficacy and tolerability of terbinafine (Lamisil) used systemically in the treatment of dermatomycosis of skin and nails. J Dermatol Treat 1990; 1 (Suppl. 2): 33-8.
10. Striker BH, de-Jong PA, Schreuder Fet et al. Loss of taste sensation in terbinafine administration. Ned Tijdschr Geneeskd 1992; 136: 2438-40.
11. Striker BII, Otterranger JP. Recording of possible side effects in Bureau for side effects of drugs and research activities in 1992, Ned Tijdschr Geneeskd 1995; 137: 1784-7.
12. Greer DL. Clinical consequences of new pharmacological concepts in cutaneous fungal infections. J Eur Acad Dermatol Venerol 1993: 2 (Suppl. 1): s26-33.
13. Schuster I, Ryder NS. Allylamines-mode and selectivity of action compared to azole antifungals and biological fate in mammalian organisms. J Dermatol Treat 1990; 1 (Suppl. 2): 7-9.